The sesquiterpene lactone eupatolide sensitizes breast cancer cells to TRAIL through down-regulation of c-FLIP expression

JONGKYU LEE¹, CHEOL HWANGBO¹, JUNG JOON LEE², JUHEE SEO¹ and JEONG-HYUNG LEE¹

¹Department of Biochemistry, College of Natural Sciences, Kangwon National University, Chuncheon 200-701;
²Molecular Cancer Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon 305-600, Korea

Received June 22, 2009; Accepted September 2, 2009

DOI: 10.3892/or_0000628

Abstract. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a promising candidate for cancer therapeutics due to its ability to induce apoptosis selectively in cancer cells. However, sensitivity of cancer cells for induction of apoptosis by TRAIL varies considerably. Therefore, it is important to develop agents that overcome this resistance. We show, for the first time, that eupatolide, the sesquiterpene lactone isolated from the medicinal plant Inula britannica, sensitizes human breast cancer cells to TRAIL-induced apoptosis. Treatment with TRAIL in combination with subtoxic concentrations of eupatolide enhanced the TRAIL-apoptosis. Treatment with TRAIL in combination with subtoxic concentrations of eupatolide enhanced the TRAIL-induced apoptosis in MCF-7, MDA-MB-231 and MDA-MB-453 breast cancer cells, whereas each reagent alone slightly induced cell death. The combination induced sub-G1 phase DNA content and annexin V-staining in MCF-7 cells, which are major features of apoptosis. Apoptotic characteristics induced by the combined treatment were significantly inhibited by a pan-caspase inhibitor. The sensitization to TRAIL-induced apoptosis was accompanied by the activation of caspase-8 and was concomitant with Bid and poly(ADP-ribose) polymerase (PARP) cleavage. Treatment of eupatolide alone significantly down-regulated the expression of cellular FLICE inhibitory protein (c-FLIP) in MCF-7 cells. Furthermore, enforced expression of c-FLIP significantly attenuated the apoptosis induced by this combination in MCF-7 cells, suggesting a key role for c-FLIP down-regulation in these events. We also observed that eupatolide inhibited AKT phosphorylation in a dose- and time-dependent manner. Moreover, inhibition of Akt by LY294002, a specific PI3K inhibitor, down-regulated the expression of c-FLIP significantly attenuated the apoptosis induced by this combination in MCF-7 cells, suggesting a key role for c-FLIP down-regulation in these events. We also observed that eupatolide inhibited AKT phosphorylation in a dose- and time-dependent manner. Moreover, inhibition of Akt by LY294002, a specific PI3K inhibitor, down-regulated the expression of c-FLIP in MCF-7 cells. Taken together, these results indicate that eupatolide could augment TRAIL-induced apoptosis in human breast cancer cells by down-regulating c-FLIP expression through the inhibition of AKT phosphorylation and be a valuable compound to overcome TRAIL resistance in breast cancer cells.

Introduction

Apoptosis is an essential process in human development, immunity and tissue homeostasis. The two primary apoptotic pathways are the death receptor and mitochondrial pathways (1,2). Apoptotic signaling and execution through these two pathways is dependent on caspases, a group of cysteine proteases that degrade a critical set of cellular proteins near specific aspartic acid residues (3). In the death receptor pathway, the apoptosis-promoting members of the tumor necrosis factor superfamily, such as TRAIL and Fas ligand, engage their respective death receptors, DR4/DR5 or Fas, which homotypically bind to the adaptor protein FADD. FADD then recruits the initiating procaspases-8 and -10 through homophilic death effector domain interactions to form the death inducing signaling complex (DISC) (4,5). The close proximity of the initiator caspases in the DISC facilitates their dimerization and activation. The active caspase-8 cleaves downstream effector caspases such as caspases-3, -6, and -7, as well as the pro-apoptotic protein Bid which initiates the mitochondrial apoptotic process (6). Cleaved Bid activates downstream pro-apoptotic proteins such as Bax and Bak which promote cytochrome c release from the mitochondria into the cytosol, thereby linking the two pathways (6). Cytochrome c associates with caspase-9, dATP and APAF-1 forming the apoposome complex leading to the activation of caspase-9, which cleaves the downstream effector caspases (7,8). Effector caspase activation promotes cellular disintegration by the cleavage of multiple cellular proteins such as PARP (9).

TRAIL belongs to the tumor necrosis factor (TNF) cytokine family and is a promising cancer drug because it induces apoptosis almost specifically in cancer cells (10,11). TRAIL has been shown to induce apoptosis of breast cancer cell lines, although the sensitivity varies considerably, with the majority of cell lines being relatively resistant (12,13). One issue of concern in TRAIL-based therapies is that a considerable number of tumor cells are resistant to TRAIL-induced apoptosis. Therefore, it is important to identify substances that potently restore TRAIL sensitivity in TRAIL resistance cells. TRAIL binds to the death-receptors DR4/DR5. Procaspase-8 zymogens are recruited by FADD to the DISC where they are

Key words: eupatolide, tumor necrosis factor-related apoptosis-inducing ligand, apoptosis, cellular FLICE inhibitory protein, AKT
Proteins were extracted from cells in Western blot analysis from at least 3 independent experiments. The protein expression levels are presented as the mean ± SD of triplicate determinations performed with 1 μg/ml leupeptin, 1 mM sodium vanadate, 150 mM NaCl). Fifty μg of protein per lane was separated by sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis (PAGE) and followed by transferring to a polyvinylidene difluoride membrane (Millipore, Bedford, MA, USA). The membrane was blocked with 5% skim milk and then incubated with the corresponding antibody. Antibodies for caspase-8, PARP, Bid, c-FLIP, Bax, Bcl-2, c-IAP1, c-IAP2, p-Akt (Ser473) and Akt were purchased from Cell Signaling Technology (Beverly, MA, USA). Antibody for α-tubulin was from Sigma (St. Louis, MO, USA). After binding of an appropriate secondary antibody coupled to horseradish peroxidase, proteins were visualized by enhanced chemiluminescence according to the instructions of the manufacturer (Amersham Pharmacia Biotec, Buckinghamshire, UK).

Reverse transcription-polymerase chain reaction (RT-PCR). MCF-7 cells were treated with eupatolide alone or in combination with 100 ng/ml of TRAIL for the indicated times. The cells were harvested and total RNA was isolated using RNeasy mini kits (Qiagen, Santa Clarita, CA, USA) according to the manufacturer's instructions. Two μg of total RNA was used to synthesize 1st stranded cDNA using RT-PCR kit (Invitrogen, Carlsbad, CA, USA). For amplification of the c-FLIP L and c-FLIP S, the following primers were used: c-FLIP L, 5'-CAGAGATTGGATGAGTAGTTGGAATAA TCTG-3' (sense), 5'-CCTAGGGCTTGCTCTCTTCACTTT GTA-3' (antisense), c-FLIP S, 5'-CAGAGATTGGATGAGG AGATGGATAAACATCGT-3' (sense), 5'-GGAAACATTTCA AGAATTTCCAGATGG-3' (antisense). The cDNA for GAPDH was also amplified as a control in a similar way using the following primers: 5'-ACCAAGATGGCTCATGC CATCAC-3' (sense), 5'-TCCACCAACCCTGTCGTGTA-3' (antisense). For PCR amplification, the following conditions were used: 94˚C for 2 min for 1 cycle and then 94˚C for 1 min, 57˚C for 30 sec and 72˚C for 1 min for 30 cycles. The amplified PCR products were separated with 1.5% agarose gel and then stained with EtBr.

Apopotis detection. The extent of apoptosis was evaluated with hypodiploid content of DNA and annexin V-staining. MCF-7 cells were treated with 10 μM eupatolide in the absence or presence of 100 ng/ml TRAIL for 24 h. For the determination of hypodiploid content of DNA, the cells were washed twice with cold PBS and then centrifuged. Briefly, the pellet was fixed in 75% (vol/vol) ethanol for 1 h at 4˚C. The cells were washed once with PBS and resuspended in cold propidium iodide solution (50 μg/ml) containing RNase A (0.1 mg/ml) in PBS (pH 7.4) for 30 min in the dark. Flow cytometry analyses were performed using FACSCalibur (Becton-Dickinson, San Jose, CA, USA). Forward light scatter characteristics were used to exclude the cell debris from the analysis. The sub-G₁ population was calculated to estimate the apoptotic cell population. The CellQuest software was used to analyze the data (Becton-Dickinson). Annexin V-staining was performed using annexin V-FITC apoptosis detection kit (BD Biosciences, CA, USA) following the instructions of the manufacturer. Briefly, after incubation, the cells were harvested, washed with PBS (pH 7.4), centrifuged and stained with annexin V-FITC and 2 μg/ml propidium iodide in binding buffer (10 mM Hepes, pH 7.4, 140 mM NaCl, 2.5 mM CaCl₂).
for 15 min at 37˚C in the dark. The samples were analyzed by flow cytometry using a FACSscan flow cytometer. The CellQuest software was used to analyze the data (Becton-Dickinson).

**Detection of DR-4 and DR-5 expression on cell surface.**

MCF-7 cells treated with the eupatolide or vehicle alone for 16 h were harvested, washed with PBS and suspended in PBS containing 1% bovine serum albumin. Then, 3 μl of phycoerythrin-conjugated anti-DR5, anti-DR4, or mouse IgG control antibody (eBiosciences, CA, USA) were added to cells and incubated on ice for 30 min. After washing with PBS, DR5 and DR4 expression on cell surface was analyzed in FITC-positive cell population by flow cytometry.

**Statistical analysis.** Data represent mean ± SD of triplicate data. Data were analyzed using a Student's t-test and differences were considered significant from controls at P<0.05.

Figure 1. Induction of cell death in human breast cancer cell lines by eupatolide and TRAIL. (A) Chemical structure of eupatolide. (B) Effect of eupatolide on TRAIL-induced cell death. Cells were seeded in triplicates into 96-well plates and cultured with eupatolide (0-10 μM) alone, or in combination with TRAIL (0-100 ng/ml) for 24 h. Cell viability was determined by MTT assay. Data are presented as the mean ± SD from two independent experiments, and are expressed as a percentage of the number of control cells.
Results

Eupatolide cooperates with TRAIL to induce death of breast cancer cells. The cytotoxic activity of TRAIL was tested with MTT assays in three human breast cancer cell lines: MCF-7, MDA-MB-453 and MDA-MB-231 (Fig. 1). Treatment of 10 to 100 ng/ml of TRAIL induced limited cell death (<15%) over 24 h, suggesting that these breast cancer cell lines are resistance to the cytotoxic effect of TRAIL. Next, we investigated the cytotoxic effect of eupatolide alone or in combination with TRAIL in these cells. Eupatolide alone did not show significant cytotoxic effect up to 10 μM. However, cell viability was significantly reduced by the combined treatment both when holding the concentration of TRAIL fixed and varying the concentration of eupatolide and when holding the concentration of eupatolide fixed and varying the concentration of TRAIL. Treatment of MCF-7 cells with 100 ng/ml of TRAIL or 10 μM of eupatolide reduced cell viability to 12±2 and 5±0.3%, respectively, of control level at 24 h. However, combined treatment of 100 ng/ml of TRAIL and 10 μM of eupatolide resulted in the reduction of cell viability to 43±5% of control level (Fig. 1A). Similar results were observed in MDA-MB-231 and MDA-MB-453 cells (Fig. 1B). These results show that combined treatment of eupatolide and TRAIL effectively induces cell death in these breast cancer cell lines.

Eupatolide sensitizes MCF-7 cells to TRAIL-induced apoptosis. We then investigated whether apoptotic cell death is induced by a combination of eupatolide and TRAIL in MCF-7 cells. In order to quantify apoptosis induction, we measured the amount of hypodiploid cell populations using flow cytometric analysis. Cotreatment of MCF-7 cells with 10 μM eupatolide and 100 ng/ml TRAIL for 24 h significantly increased the accumulation of sub-G1 phase cells, whereas treatment with eupatolide or TRAIL alone did not (Fig. 2A). Pretreatment with a pan-caspase inhibitor (caspase inhibitor II) significantly blocked the accumulation of sub-G1 phase cell populations induced by eupatolide plus TRAIL (Fig. 2A). Annexin V/PI staining assays also revealed that combined treatment of eupatolide plus TRAIL significantly induced apoptosis and a pan-caspase inhibitor significantly blocked the induction of apoptosis (Fig. 2B). As the TNF superfamily members reportedly share similar protein structures and death receptor-mediated apoptotic signaling pathways (24), we next tested whether eupatolide could also sensitize TNF-α-mediated apoptosis. Similar with our TRAIL results, eupatolide also sensitizes MCF-7 cells to TNF-α-induced apoptosis and a pan-caspase inhibitor suppressed this effect (Fig. 2C). Collectively, these results suggest that eupatolide stimulates TRAIL-induced, caspase-dependent apoptosis, possibly targeting the common component(s) of the death receptor-mediated apoptotic pathway.

Combination with eupatolide and TRAIL results in the caspase-8 activation and PARP cleavage, but does not alter the expression of DR4/DR5. To delineate the mechanisms by which eupatolide promotes TRAIL-induced apoptosis, MCF-7 cells were treated with 100 ng/ml of TRAIL alone or in combination with 10 μM of eupatolide for 12 h. Cell lysates were then analyzed by immunoblotting for proteolytic processing of procaspase-8, the caspase-8 substrate Bid, and caspase-3 substrate PARP (Fig. 3A). Treatment with 10 μM of eupatolide or 100 ng/ml of TRAIL alone was barely
detectable the proteolytic processing of procaspase-8, Bid and PARP. However, combined treatment with eupatolide and TRAIL resulted in robust procaspase-8 processing, Bid cleavage and PARP proteolysis. Because TRAIL is known to trigger apoptotic signals via two types of death receptors, DR4 and DR5 (25,26), we next investigated whether the modulation of DR4 and/or DR5 expression levels by eupatolide might be involved in its sensitizing effect on TRAIL-induced apoptosis (Fig. 3B). FACS analysis showed that eupatolide did not modulate the surface expression levels of DR4 and DR5 in MCF-7 cells.

**TRAIL sensitization by eupatolide is mediated by down-regulation of c-FLIP protein expression, but not mRNA expression.** We next examined the effect of eupatolide on the expression of apoptosis-regulating proteins in MCF-7 cells (Fig. 4A). The expression levels of Bcl-2, IAP-1, IAP-2 and Bax were not changed by eupatolide alone or cotreatment with eupatolide and TRAIL. However, eupatolide alone significantly down-regulated the expression of both c-FLIP<sub>L</sub> and c-FLIP<sub>S</sub>. In addition, the expression levels of c-FLIP<sub>L</sub> and c-FLIP<sub>S</sub> were markedly decreased by cotreatment with eupatolide and TRAIL. To examine whether eupatolide-induced down-regulation of c-FLIP is controlled at the transcriptional level, we performed RT-PCR analysis of c-FLIP<sub>L</sub> and c-FLIP<sub>S</sub> (Fig. 4B). We found that the mRNA expression levels of c-FLIP<sub>L</sub> and c-FLIP<sub>S</sub> were not changed by eupatolide alone or cotreatment with eupatolide and TRAIL, suggesting that down-regulation of c-FLIP<sub>L</sub> and c-FLIP<sub>S</sub> expression could be regulated at the post-transcriptional level. To further confirm the inhibitory effect of eupatolide on the c-FLIP protein levels, MCF-7 cells were treated with 10 μM of eupatolide for 6, 12 and 24 h and then the expression levels of c-FLIP<sub>L</sub> and c-FLIP<sub>S</sub> were determined (Fig. 4C and D). We found that treatment of 10 μM of eupatolide resulted in the gradual decrease in the protein expression levels of c-FLIP<sub>L</sub> and c-FLIP<sub>S</sub> by 24 h (Fig. 4C). However, the mRNA expression levels did not change by this treatment (Fig. 4D).

To clarify the functional role of c-FLIP in sensitization of TRAIL-induced apoptosis by eupatolide, we examined the effect of c-FLIP overexpression on the apoptosis induced by cotreatment with eupatolide and TRAIL (Fig. 4E). Overexpression of c-FLIP significantly inhibited the sensitizing effect of eupatolide on the TRAIL-induced apoptosis in MCF-7 cells, suggesting that eupatolide-induced down-regulation of c-FLIP plays a critical role in enhancement of TRAIL-induced apoptosis in MCF-7 cells.

**Down-regulation of c-FLIP by eupatolide is mediated via inhibition of AKT phosphorylation.** It has been reported that PI3K/Akt pathway is involved in the regulation of c-FLIP expression, which is a key mediator of TRAIL resistance in several human cancer cells (27-29). Therefore, we investigated whether eupatolide might inhibit the activity of Akt. MCF-7 cells were treated with 10 μM of eupatolide for the indicated times and then the expression level of phospho-Akt was determined by immunoblotting using phospho-specific S473 Akt antibody (Fig. 5A). We found that treatment of 10 μM of eupatolide resulted in gradually decreased the phosphorylation levels of Akt by 6 h. Furthermore, eupatolide inhibited the phosphorylation of Akt in a dose-dependent manner (Fig. 5B). In order to address the possible link between Akt and c-FLIP expression, we next examined whether inhibition of Akt down-regulates the expression of c-FLIP in MCF-7 cells (Fig. 5C). Preincubation of eupatolide or the PI3K inhibitor LY294002 significantly suppressed both c-FLIP...
Figure 4. Effect of eupatolide on the expression level of c-FLIP. (A) MCF-7 cells were treated with 10 μM eupatolide alone, or in combination with 100 ng/ml TRAIL for 24 h. The cell lysates were analyzed by Western blotting with specific antibodies (anti-c-FLIP, anti-cIAP1, anti-cIAP2, anti-Bax and anti-Bcl2). The data are representative of three independent experiments. (B) RT-PCR analysis of c-FLIP mRNA expression. MCF-7 cells were treated as described (A). Total RNA was isolated, and the expression levels of c-FLIPL, c-FLIPS and GAPDH were determined by RT-PCR. (C and D) Effect of eupatolide on the expression of protein (C) and mRNA (D) of c-FLIP. MCF-7 cells were incubated with eupatolide (10 μM) for the indicated times. The expression levels of FLIPL and FLIPS were analyzed by Western blotting (C) or RT-PCR (D). (E) Effect of c-FLIP overexpression on the eupatolide-mediated sensitization of TRAIL-induced apoptosis. MCF-7 cells were transiently transfected with a Flag-tagged c-FLIPS expression vector. After 48 h, the cells were treated with 10 μM eupatolide and 100 ng/ml TRAIL and further incubated for the additional 24 h. Apoptosis levels were determined as the percentage of cells with hypodiploid content of DNA in the pre-G0/G1 region using flow cytometry. Data are presented as the mean ± SD from three independent experiments. Asterisks indicate a significant difference compared to the control.
Members of the TNF receptor superfamily, including TNF receptor, Fas and TRAIL receptor, share similar conserved structures (24). Although TNF-α and FasL can trigger apoptosis in some solid tumors, their clinical usage has been limited by the risk of lethal systemic inflammation and hepatotoxicity, respectively (30,31). TRAIL selectively induces apoptosis in cancer cells in vitro and in vivo with little or no toxicity toward normal cells (10,11). Therefore, TRAIL is one of the most promising new candidates for anti-tumor therapeutics. However, previous studies have shown that considerable numbers of cancer cells are resistant to the apoptotic effects of TRAIL (12,13,32). Thus, it is of importance to develop agents that sensitize cancer cells to TRAIL-induced apoptosis to improve therapeutic impact of TRAIL.

In this study, we investigated the ability of eupatolide, a naturally occurring member of sequiterpene lactone, to enhance TRAIL-induced apoptosis in human breast cancer cells. We showed for the first time that subtoxic doses of eupatolide sensitize human breast cancer cells to TRAIL-induced apoptosis by down-regulating c-FLIP expression. Cellular sensitivity to TRAIL can be affected by the expression levels of the cell membrane TRAIL receptors, caspase-8, or c-FLIP (32). Moreover, it has been reported that down-regulation of c-FLIP is sufficient to confer sensitivity against TRAIL- and FasL-mediated apoptosis (33,34). We found that eupatolide causes a significant decrease in the levels of proteins for c-FLIP<sub>L</sub> and c-FLIP<sub>S</sub>, but the expression of cell membrane TRAIL receptors, DR4 and DR5 was not changed in MCF-7 breast cancer cells. We also showed that overexpression of c-FLIP significantly inhibited the apoptosis induced by the combination of eupatolide and TRAIL in MCF-7 cells, confirming that down-regulation of c-FLIP by eupatolide is functionally significant in sensitizing the effect of eupatolide on TRAIL-mediated apoptosis. Several studies have demonstrated that certain compounds, such as synthetic triterpenoids, honokiol, and flavopiridol, can induce down-regulation of c-FLIP and subsequent sensitization of TRAIL-induced apoptosis in cancer cells (35-37). Similar with these compounds, eupatolide was able to sensitize cancer cells to TRAIL-induced apoptosis by down-regulating c-FLIP. It is noteworthy that eupatolide sensitized MCF-7 cells to TNF-α-induced apoptosis. As a structural homologue of caspase-8, c-FLIP binds FADD, competing with caspase-8 for recruitment to DISC. Therefore, c-FLIP suppression by eupatolide could be involved in mediating the sensitization of cancer cells to TNF-α or TRAIL-induced apoptosis. Regarding TRAIL receptors, certain compounds, such as celecoxib, kaemferol and sulforaphane, sensitize cancer cells to TRAIL-induced apoptosis by up-regulation of DR5 (38-40). Eupatolide did not modulate the expression of DR4 and DR5, suggesting that TRAIL receptors could not be of particular importance in eupatolide facilitated TRAIL-induced apoptosis.

In several types of cancers, increased c-FLIP expression is correlated with resistance to TRAIL-, Fas-, or TNF-induced apoptosis (17-19,41,42). Post-translational modification and degradation of c-FLIP as well as increased mRNA levels have been suggested to be involved in increasing c-FLIP expression (43). It has been reported that the activation of PI3K/Akt pathway inhibits the death-receptor mediated apoptotic pathway through the up-regulation of c-FLIP expression (27-29). We showed that eupatolide inhibited Akt phosphorylation in a dose- and time-dependent manner. Furthermore, inhibition of Akt by LY294002 resulted in the down-regulation of c-FLIP, indicating that eupatolide may down-regulate c-FLIP protein levels through inhibition of Akt. In agreement with our findings, a recent study showed that the alkylphospholipid perifosine, an Akt inhibitor, induces apoptosis of human lung cancer cells by down-regulating c-FLIP (44). Accordingly, inhibition of Akt by eupatolide could contribute to the down-regulation of c-FLIP. However, the detailed mechanism by which eupatolide regulates the expression of c-FLIP remains to be elucidated.

Taken together, we have found that eupatolide, a sesquiterpene lactone from I. britannica, enhanced TRAIL-mediated apoptosis in human breast cancer cells, which appeared to be mediated through a mechanism involving inhibition of c-FLIP expression and Akt activation. Eupatolide expression and Akt phosphorylation, suggesting that inhibition of Akt phosphorylation by eupatolide could be involved in the eupatolide-induced down-regulation of c-FLIP.
may a valuable compound for sensitizing TRAIL-induced apoptosis in breast cancer cells.

Acknowledgements

This work was supported by a grant from the Korea Healthcare technology R&D Project, Ministry for Health and Welfare, Republic of Korea (No. A080405).

References


